Summary#
The bill directs the Department of Health and Human Services (HHS) to set maximum permissible contaminant levels for infant formula. It adds noncompliance with those contaminant levels to the law’s definition of an “adulterated” infant formula. The bill aims to reduce infant exposure to contaminants and increase testing and reporting by formula makers.
- Main change: HHS must write rules that set maximum contaminant levels for infant formula and require manufacturers to test and keep records.
- Contaminants covered: The bill lists heavy metals, PFAS (per- and polyfluoroalkyl substances), phthalates, microplastics, synthetic pesticides, biological toxins (including cyanotoxins), and other man-made pollutants.
- Enforcement and reporting: Manufacturers must test and keep test records for 2 years after a product’s shelf life. HHS must include violations and detected contaminant concentrations in its annual report to Congress.
- Timing: HHS must issue implementing regulations within 180 days of the law’s enactment. The rules would apply to formulas made 180 days after the rules are issued.
What it means for you#
- Manufacturers: Must test infant formula for contaminants, meet the new maximum levels once set, keep test records for 2 years after shelf life, and provide records to HHS on request. Noncompliance can make a product “adulterated,” which can trigger enforcement actions.
- Parents and caregivers: The bill is meant to lower contaminants in formula. It does not itself set any specific contaminant limits; those will be set later by HHS. This could lead to changes in which brands or batches are available if some do not meet the new limits.
- HHS / FDA (the agency within HHS that enforces food law): Must write and publish the regulations within 180 days, set the maximum contaminant levels, oversee testing and record requests, and include certain data (violations and measured contaminant levels) in its annual report to Congress.
- Retailers and distributors: Could face supply changes or product recalls if manufacturers cannot meet the new limits. The bill does not directly impose new obligations on retailers, but they may be affected by availability.
- Public health monitoring: The annual report required by the bill would provide public data on contaminant concentrations found in surveillance testing and identify manufacturers found in violation.
Expenses#
No direct public cost estimate is included in the bill text or materials supplied.
- The bill would likely increase compliance costs for formula manufacturers (testing, lab work, recordkeeping, and possibly reformulation or new sourcing).
- HHS/FDA may face increased administrative and enforcement costs to write rules, review records, run surveillance testing, and compile the annual report.
- There could be indirect costs if stricter limits reduce available supply or raise prices; the bill itself takes cost into account when setting levels but does not estimate economic impacts.
- No fiscal note or budget estimate is provided in the supplied material.
Proponents' View#
- The bill appears intended to reduce infants’ exposure to harmful contaminants and protect infant neurodevelopment by requiring clear contaminant limits.
- It would create routine testing and recordkeeping rules for manufacturers, increasing transparency about contaminant levels.
- Annual reporting to Congress (including measured concentrations and violations) could improve oversight and public information about the safety of the domestic infant formula supply.
- The bill requires HHS to use available technology and consider cost when setting limits, which could balance safety and feasibility.
Opponents' View#
- One concern is the short timeline: HHS must write regulations within 180 days, and manufacturers must comply for products made 180 days after regulations are issued. That may be a tight schedule for testing capability, supply-chain changes, or reformulation.
- The bill does not set specific numerical limits itself. It leaves key details—how strict the limits will be and how the “maximum contaminant level goal” is defined—to HHS rulemaking. This creates uncertainty until rules are published.
- Testing, recordkeeping, and potential reformulation could raise costs for manufacturers. Those costs could affect prices or supply, but the bill does not estimate those effects.
- Enforcement and monitoring will require agency resources; the bill does not include funding or a fiscal estimate for increased HHS/FDA workload.
- It is unclear how the bill’s requirement to consider “cost” when setting levels will be applied in practice, and whether that could lead to weaker limits than some public-health groups might prefer.